Weijian Medical Helps Boao Lecheng Online Policy Promotion Conference Successfully Held in Japan

Qionghai, Hainan September 22, 2021/PRNewswire/ - September 16, 2021 (China/Boao), hosted by Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration (referred to as "Lecheng Administration") , Hong Kong Weijian Pharmaceutical Group Co.

At the meeting, Li Yunda, Deputy Director of Hainan Provincial Drug Administration, Gu Gang, Director of Lecheng Administration, and Bo Pei, Senior International Affairs Officer of Lecheng Administration, respectively delivered welcome speeches.

Kyowa Kirin Co.

Gu Gang, Director of Lecheng Administration Bureau

Gu Gang, director of the Lecheng Administration Bureau, said that Lecheng, as a highly open medical park, welcomes the arrival of Japanese pharmaceutical companies, and will do its best to help enterprises’ innovative products to be displayed, promoted and applied in Lecheng, so that international medical The technological innovations benefited Chinese patients earlier

Li Yunda, Deputy Director of Hainan Provincial Drug Administration

Li Yunda, deputy director of the Hainan Provincial Drug Administration, pointed out that since the State Council granted the Hainan People’s Government in 2018 the unprecedented "examination and approval authority for clinically urgently needed imported drugs and medical devices", 173 varieties of clinically urgently needed drugs and medical devices have been approved for import, 5380 Patients benefit

Lv Xiaolei, deputy director of the Lecheng Administration Bureau, pointed out that the "Opinions on Supporting the Construction of Hainan Free Trade Port to Relax Certain Special Measures for Market Access" gave Lecheng a new pilot policy, which will further simplify the approval process.

Chen Pingyan, executive director of the Hainan Real World Data Research Institute, pointed out that in the process from real world data to evidence, high-quality data, good design, and correct analysis and result interpretation are three key links

Xiao Li, the vice president of Hong Kong Weijian Pharmaceutical Group, said that with the support of the Lecheng Pioneer Zone policy, the Center for Rare Diseases has introduced 31 rare disease products since its establishment.

In this promotion conference, Weijian Pharmaceutical gave full play to the Group’s mature international business network and strong BD capabilities in Japan, and successfully invited nearly 70 Japanese companies to participate in the conference, which enhanced the policies and policies of many Japanese companies on Lecheng.

In the future, under the policy of opening the Lecheng pioneer area, Hong Kong Weijian Pharmaceutical Group will continue to use the introduction of the rare disease center's products as an opportunity for cooperation to further promote and deepen the long-term cooperation between Lecheng and participating Japanese companies, and actively promote franchising.

About Lecheng Pioneer District

Hainan Boao Lecheng International Medical Tourism Pioneer Zone was established with the approval of the State Council in February 2013 to pilot the development of international medical tourism related industries such as licensed medical care, tumor prevention, health management, care and rehabilitation, medical beauty and anti-aging, aiming to realize medical technology and equipment , Pharmaceuticals and the international advanced level "three synchronizations", is currently the only medical industry park in the country that is open to the outside world

About Lecheng Administration

Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration was formally established in August 2019 in accordance with Hainan Provincial Government Order No.

About Weijian Pharmaceutical

Hong Kong Weijian Pharmaceutical Group was established in 2006.

About Boao Lecheng Weijian Rare Disease Clinical Medicine Center

The Boao Lecheng Weijian Rare Disease Clinical Medicine Center was established on April 10, 2020 in the Boao Lecheng International Medical Tourism Pioneer Zone, Hainan, China.

The center’s mission is to "synchronize with the world, and is committed to introducing the most advanced rare disease products into the Chinese market, and bringing unprecedented hope to rare disease patients and families in China and neighboring countries and regions"; committed to becoming China and Southeast Asia Such as rare disease clinical medicine centers with the most comprehensive and advanced rare disease products and the highest-end diagnosis and treatment services in the surrounding areas

Source: Weijian Pharmaceutical